Louisiana State Employees Retirement System Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Louisiana State Employees Retirement System lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,700 shares of the specialty pharmaceutical company’s stock after purchasing an additional 600 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Supernus Pharmaceuticals were worth $741,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Fidelis Capital Partners LLC purchased a new stake in Supernus Pharmaceuticals in the 1st quarter valued at about $33,000. EntryPoint Capital LLC purchased a new position in shares of Supernus Pharmaceuticals during the first quarter worth $43,000. Quadrant Capital Group LLC raised its holdings in shares of Supernus Pharmaceuticals by 1,117.6% in the 4th quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 1,330 shares during the period. Covestor Ltd lifted its stake in Supernus Pharmaceuticals by 15.3% during the 1st quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 358 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Supernus Pharmaceuticals in the 1st quarter valued at about $129,000.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $35.00 on Friday. The firm has a market capitalization of $1.93 billion, a PE ratio of -120.69 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $21.99 and a fifty-two week high of $35.44. The stock’s 50-day simple moving average is $30.14 and its 200-day simple moving average is $30.01.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.39 by ($0.03). The firm had revenue of $168.30 million for the quarter, compared to analyst estimates of $148.83 million. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.02) EPS. On average, sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Piper Sandler downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.